Caplin Steriles Limited has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Cisatracurium Besylate Injection USP, 10 mg/5 mL (2 mg/mL) and 200 mg/20 mL (10 mg/mL) Single-dose Vials; and 20 mg/10 mL (2 mg/mL). Multiple-dose Vials (Preserved)., a generic therapeutic equivalent version of (RLD), NIMBEX injection of AbbVie Inc. Cisatracurium besylate Injection USP is a nondepolarizing skeletal neuromuscular blocker, indicated as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgical procedures. According to IQVIATM (IMS Health), Cisatracuriumesylate Injection USP had US sales of approximately $35 million for the 12-month period ending December 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,480 INR | +7.28% | +5.69% | +9.16% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.16% | 1.26B | |
+20.39% | 43.67B | |
+26.21% | 22.79B | |
+21.43% | 15.45B | |
+18.82% | 14.29B | |
+53.37% | 12.83B | |
-0.05% | 6.79B | |
-11.88% | 6.52B | |
-8.87% | 5.73B | |
+12.62% | 5.59B |
- Stock Market
- Equities
- CAPLIPOINT Stock
- News Caplin Point Laboratories Limited
- Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP